ClinicalTrials.gg
CompletedNCT02185534Updated Jun 22, 2016Results posted

Clopidogrel Bioequivalence Study in Healthy Subjects

A Phase 1 interventional study of Clopidogrel in Bioequivalence, AUC, Cmax, Pharmacokinetics, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-22.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will be an open-label, randomised, three-way crossover study in healthy male and female subjects, performed at a single centre. The objective of the study is to assess the bioequivalence between one test formulation (Clopidogrel 75 mg tablet (commercial blister from KRKA) and two reference formulations (Clopidogrel 75 mg tablet [Plavix, sourced in US and Japan]).

Read the detailed description

Study to evaluate the bioequivalence of orally administered European source clopidogrel tablets and US and Japanese source clopidogrel tablets.

02

Conditions studied

  • Bioequivalence, AUC, Cmax, Pharmacokinetics

Keywords

  • Clopidogrel, Zyllt, Plavix, Phase I, Healthy Subjects, Pharmacokinetics, Bioequivalence
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects aged 18 to 55 years with suitable veins for cannulation or repeated venepuncture.
  • Females must have a negative pregnancy test at screening and on each admission to the clinical unit, must not be lactating and

    • if of non , confirmed at screening by fulfilling one of the following criteria:
  • defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle-stimulating hormone (FSH) levels in the post-menopausal range.
  • Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.

    • if of child-bearing potential and are sexually active must use, with their partner, 2 approved methods of highly effective from the time of IMP administration until 3 months after the last dose of IMP.
  • Have a between 18,5 and 29.9 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
  • Be able to understand, read and speak the German language.

Exclusion criteria

Exclusion criteria

  • History of any disease or disorder which, in the opinion of the Investigator, may either put the potential subject at risk because of participation in the study, or influence the results or the potential subject's ability to participate in the study.
  • Current smokers or those who have smoked or used nicotine products within the previous 3 months.
  • History of haemophilia, von Willebrand's disease, lupus anticoagulant, or other diseases/syndromes that can either alter or increase the propensity for bleeding.
  • A personal history of vascular abnormalities including aneurysms; a personal history of severe haemorrhage, haematemesis, melena, haemoptysis, severe epistaxis, severe thrombocytopenia, intracranial haemorrhage; or rectal bleeding within 1 year prior to screening; or history suggestive of peptic ulcer disease; or at the discretion of the Investigator.
  • Use of aspirin, ibuprofen, NSAIDS, or any other drug known to increase the propensity for bleeding for 2 weeks before randomisation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    European clopidogrel tablets, 75 mg

    Treatment A: a single oral dose of clopidogrel 75 mg film-coated tablet (Zyllt, KRKA - test)

    Drug: Clopidogrel

  • Active comparator
    Japanese clopidogrel tablets, 75 mg

    Treatment B: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Brystol-Myer Squibb,Sanofi-Aventis, reference)

    Drug: Clopidogrel

  • Active comparator
    US clopidogrel tablets, 75 mg

    Treatment C: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Sanofi-Aventis, reference)

    Drug: Clopidogrel

Interventions

  • European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference)

    Also known as: Zyllt, Plavix

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))

    Comparison of the pharmacokinetic profile in terms of plasma concentration-time curve from time zero extrapolated to infinity, AUC(0-inf), of clopidogrel sourced in Europe and Japan.

    Time frame: 0 hours (pre-dose), as well as at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hours post-dose

  2. Pharmacokinetics of Clopidogrel by Assessment of Observed Maximum Plasma Concentration (Cmax)

    Comparison of the pharmacokinetic profile in terms of observed maximum plasma concentration, taken directly from the individual concentration-time curve, Cmax, of clopidogrel sourced in Europe and the US.

    Time frame: 0 hours (pre-dose), as well as at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hours post-dose

Secondary outcomes

  1. Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-last))

    Comparison of the pharmacokinetic profile in terms of the area under the plasma concentration-curve from time zero to the time of last quantifiable clopidogrel or SR26334 concentration, AUC(0-last), of clopidogrel sourced in Europe and the US.

    Time frame: 0 hours (pre-dose), as well as at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hours post-dose

07

Results

Posted Nov 30, 2015

Participant flow

Participants recruited at PAREXEL Early Phase Clinical Unit Berlin, Germany between August 2014 and September 2014.

First Period
Participant flow — First Period
MilestoneFirst European, Then Japanese, Then US ClopidogrelFirst European, Then US, Then Japanese ClopidogrelFirst Japanese, Then European, Then US ClopidogrelFirst Japanese, Then US, Then European ClopidogrelFirst US, Then European, Then Japanese ClopidogrelFirst US, Then Japanese, Then European Clopidogrel
Started141414141414
Completed141414131414
Not completed000100
Withdrew: Withdrawal by subject000100
First Washout Period
Participant flow — First Washout Period
MilestoneFirst European, Then Japanese, Then US ClopidogrelFirst European, Then US, Then Japanese ClopidogrelFirst Japanese, Then European, Then US ClopidogrelFirst Japanese, Then US, Then European ClopidogrelFirst US, Then European, Then Japanese ClopidogrelFirst US, Then Japanese, Then European Clopidogrel
Started141414131414
Completed131414131313
Not completed100011
Withdrew: Withdrawal by subject100010
Withdrew: Protocol violation000001
Second Period
Participant flow — Second Period
MilestoneFirst European, Then Japanese, Then US ClopidogrelFirst European, Then US, Then Japanese ClopidogrelFirst Japanese, Then European, Then US ClopidogrelFirst Japanese, Then US, Then European ClopidogrelFirst US, Then European, Then Japanese ClopidogrelFirst US, Then Japanese, Then European Clopidogrel
Started131414131313
Completed131414131313
Not completed000000
Second Washout Period
Participant flow — Second Washout Period
MilestoneFirst European, Then Japanese, Then US ClopidogrelFirst European, Then US, Then Japanese ClopidogrelFirst Japanese, Then European, Then US ClopidogrelFirst Japanese, Then US, Then European ClopidogrelFirst US, Then European, Then Japanese ClopidogrelFirst US, Then Japanese, Then European Clopidogrel
Started131414131313
Completed131414131313
Not completed000000
Third Period
Participant flow — Third Period
MilestoneFirst European, Then Japanese, Then US ClopidogrelFirst European, Then US, Then Japanese ClopidogrelFirst Japanese, Then European, Then US ClopidogrelFirst Japanese, Then US, Then European ClopidogrelFirst US, Then European, Then Japanese ClopidogrelFirst US, Then Japanese, Then European Clopidogrel
Started131414131313
Completed131414131313
Not completed000000

Outcome measures

PrimaryPharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))

Comparison of the pharmacokinetic profile in terms of plasma concentration-time curve from time zero extrapolated to infinity, AUC(0-inf), of clopidogrel sourced in Europe and Japan.

Time frame:
0 hours (pre-dose), as well as at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hours post-dose
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))
ng*h/mLEuropean Clopidogrel Tablets, 75 mgJapanese Clopidogrel Tablets, 75 mgUS Clopidogrel Tablets, 75 mg
Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))1.05 ± 139.00.992 ± 117.91.09 ± 106.9
Statistical analysis
  • European Clopidogrel Tablets, 75 mg vs Japanese Clopidogrel Tablets, 75 mg · Geometric mean ratio: 104.43 · 90% CI 92.27 to 118.19Geometric mean ratio is calculated as A/B, where A= European clopidogrel and B=Japanese clopidogrel
  • European Clopidogrel Tablets, 75 mg vs US Clopidogrel Tablets, 75 mg · Geometric mean ratio: 97.19 · 90% CI 81.12 to 116.45Geometric mean ratio is calculated as A/C, where A= European clopidogrel and C=US clopidogrel
PrimaryPharmacokinetics of Clopidogrel by Assessment of Observed Maximum Plasma Concentration (Cmax)

Comparison of the pharmacokinetic profile in terms of observed maximum plasma concentration, taken directly from the individual concentration-time curve, Cmax, of clopidogrel sourced in Europe and the US.

Time frame:
0 hours (pre-dose), as well as at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hours post-dose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics of Clopidogrel by Assessment of Observed Maximum Plasma Concentration (Cmax)
ng/mLEuropean Clopidogrel Tablets, 75 mgJapanese Clopidogrel Tablets, 75 mgUS Clopidogrel Tablets, 75 mg
Pharmacokinetics of Clopidogrel by Assessment of Observed Maximum Plasma Concentration (Cmax)0.551 ± 122.60.511 ± 150.60.521 ± 122.4
Statistical analysis
  • European Clopidogrel Tablets, 75 mg vs Japanese Clopidogrel Tablets, 75 mg · Geometric mean ratio: 108.06 · 90% CI 95.46 to 122.33Geometric mean ratio is calculated as A/B, where A= European clopidogrel and B=Japanese clopidogrel
  • European Clopidogrel Tablets, 75 mg vs US Clopidogrel Tablets, 75 mg · Geometric mean ratio: 105.79 · 90% CI 95.22 to 117.53Geometric mean ratio is calculated as A/C, where A= European clopidogrel and C=US clopidogrel
SecondaryPharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-last))

Comparison of the pharmacokinetic profile in terms of the area under the plasma concentration-curve from time zero to the time of last quantifiable clopidogrel or SR26334 concentration, AUC(0-last), of clopidogrel sourced in Europe and the US.

Time frame:
0 hours (pre-dose), as well as at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hours post-dose
Reported as:
Geometric mean · h*ng/mL
Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-last))
h*ng/mLEuropean Clopidogrel Tablets, 75 mgJapanese Clopidogrel Tablets, 75 mgUS Clopidogrel Tablets, 75 mg
Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-last))0.705 ± 114.80.751 ± 116.50.767 ± 107.1
Statistical analysis
  • European Clopidogrel Tablets, 75 mg vs Japanese Clopidogrel Tablets, 75 mg · Geometric mean ratio: 93.94 · 90% CI 87.12 to 101.29Geometric mean ratio is calculated as A/B, where A= European clopidogrel and B=Japanese clopidogrel
  • European Clopidogrel Tablets, 75 mg vs US Clopidogrel Tablets, 75 mg · Geometric mean ratio: 92.03 · 90% CI 84.91 to 99.75Geometric mean ratio is calculated as A/C, where A= European clopidogrel and C=US clopidogrel

Adverse events

Collected over From screening until follow-up, i.e. up to 7 weeks after the first dose.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
European Clopidogrel Tablets, 75 mg—0/81 (0%)19/81 (23.5%)
Japanese Clopidogrel Tablets, 75 mg—0/80 (0%)18/80 (22.5%)
US Clopidogrel Tablets, 75 mg—0/82 (0%)22/82 (26.8%)
Total Number of Participants—0/83 (0%)38/83 (45.8%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventEuropean Clopidogrel Tablets, 75 mgJapanese Clopidogrel Tablets, 75 mgUS Clopidogrel Tablets, 75 mgTotal Number of Participants
DiarrhoeaGastrointestinal disorders0/811/22/23/4
HeadacheNervous system disorders16/8115/8016/8229/83
DizzinessNervous system disorders0/811/803/824/83
Abdominal PainGastrointestinal disorders1/811/801/823/83
Catheter Site PainGeneral disorders0/812/800/822/83
NauseaGastrointestinal disorders0/810/802/822/83
NasopharyngitisInfections and infestations0/810/802/822/83
ContusionInjury, poisoning and procedural complications1/810/801/822/83
PresyncopeNervous system disorders0/811/800/821/83
FatigueGeneral disorders1/810/800/821/83

Baseline characteristics

The overall number of baseline participants is 84, as it comprised all randomized subjects, although one subject withdrew consent prior to the first dose. Thus the safety population includes 83 subjects only.

Age, Continuous
Age, Continuous(years)First European, Then Japanese, Then US ClopidogrelFirst European, Then US, Then Japanese ClopidogrelFirst Japanese, Then European, Then US ClopidogrelFirst Japanese, Then US, Then European ClopidogrelFirst US, Then European, Then Japanese ClopidogrelFirst US, Then Japanese, Then European ClopidogrelTotal
Mean33 ± 937 ± 1136 ± 1035 ± 834 ± 936 ± 1135 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)First European, Then Japanese, Then US ClopidogrelFirst European, Then US, Then Japanese ClopidogrelFirst Japanese, Then European, Then US ClopidogrelFirst Japanese, Then US, Then European ClopidogrelFirst US, Then European, Then Japanese ClopidogrelFirst US, Then Japanese, Then European ClopidogrelTotal
Female77874437
Male7767101047
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)First European, Then Japanese, Then US ClopidogrelFirst European, Then US, Then Japanese ClopidogrelFirst Japanese, Then European, Then US ClopidogrelFirst Japanese, Then US, Then European ClopidogrelFirst US, Then European, Then Japanese ClopidogrelFirst US, Then Japanese, Then European ClopidogrelTotal
Black or African American1000001
White13141314121379
Other0010214
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)First European, Then Japanese, Then US ClopidogrelFirst European, Then US, Then Japanese ClopidogrelFirst Japanese, Then European, Then US ClopidogrelFirst Japanese, Then US, Then European ClopidogrelFirst US, Then European, Then Japanese ClopidogrelFirst US, Then Japanese, Then European ClopidogrelTotal
Hispanic or Latino0000213
Not Hispanic or Latino14141414121381
BMI (Body Mass Index)
BMI (Body Mass Index)(kg/m^2)First European, Then Japanese, Then US ClopidogrelFirst European, Then US, Then Japanese ClopidogrelFirst Japanese, Then European, Then US ClopidogrelFirst Japanese, Then US, Then European ClopidogrelFirst US, Then European, Then Japanese ClopidogrelFirst US, Then Japanese, Then European ClopidogrelTotal
Mean23.7 ± 3.124.7 ± 3.523.4 ± 2.924.1 ± 2.723.0 ± 3.123.9 ± 3.123.8 ± 3.0
08

Study locations

1 site
  • Research Site
    Berlin, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 9, 2014
Start
Aug 2014
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
Nov 30, 2015
Last update
Jun 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02185534
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 9, 2014
Start date
Aug 2014
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Nov 30, 2015
Last update
Jun 22, 2016

Study contacts

Rainard Fuhr, Dr. med.
principal investigator · PAREXEL International GmbH, Berlin
Glenn Carlson, MD
study director · AstraZeneca, Wilmington, US

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion